<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:979461140;
mso-list-template-ids:1571173194;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:1037925414;
mso-list-template-ids:869724184;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2
{mso-list-id:1183592855;
mso-list-template-ids:2062452150;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3
{mso-list-id:1236669332;
mso-list-template-ids:-1676483130;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.grants.gov/web/grants/view-opportunity.html?oppId=330872__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hlrK8UUs$">National Institute of Standards and Technology: Precision Measurement Grant Program (PMGP)</a><span style="color:#1F497D">
– <b>see attached notice of funding opportunity</b></span><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The PMGP is seeking applications to support significant research in the field of fundamental measurement or the determination of fundamental constants. See
<a href="https://urldefense.com/v3/__https://www.nist.gov/laboratories/projects-programs?k=&a*5B*5D=248321&tag=__;JSU!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h_SsPVR8$">
Bioscience Topic Area</a> for examples of projects/programs of interest. Notice of Funding Opportunity attached.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Abbreviated applications (~5 double spaced pages) due February 17, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: February 4.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PA-21-110.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hD5IrGwg$">Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to encourage theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or
adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of
strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. In addition to the prevention of substance use, misuse and disorder, other outcomes of interest
for the research supported through this FOA include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral
hepatitis among diverse populations and settings.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 16, 2021; June 16, 2021; October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; and October 16, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for February 2021 due date: February 3.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://pcrf-kids.org/grants-2/__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h1TKwUp0$" target="_blank">Pediatric Cancer Research Foundation: Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Pediatric Cancer Research Foundation awards three types of grants:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo1"><span style="font-family:Palatino">Emerging Investigator Fellowship Grants: $50,000 / year; can be renewed annually<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo1"><span style="font-family:Palatino">Translational Research Grants: multi-year; $100,000 / year<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo1"><span style="font-family:Palatino">Basic Science Grants: multi-year; $250,000 / year<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due March 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: February 16.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.fpwr.org/request-for-applications__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hSxhElFU$" target="_blank">Foundation for Prader-Willi Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Foundation for Prader-Willi Research addresses the many issues related to Prader-Willi Syndrome, including childhood obesity, developmental delay, psychiatric disorders, and autism spectrum disorders.
FPWR is particularly interested in supporting projects that will lead to new treatments to alleviate the symptoms associated with PWS. Funding priorities include:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo2"><span style="font-family:Palatino">Genotype to phenotype: understanding PWS genetics / how loss of PWS-critical region genes leads to the phenotype<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo2"><span style="font-family:Palatino">Neurobiology of hunger / feeding behavior in PWS<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo2"><span style="font-family:Palatino">Neurobiology of cognitive deficits, maladaptive behavior and mental illness in PWS<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo2"><span style="font-family:Palatino">Clinical care research: evaluation of existing drugs and interventions to improve health and quality of life in PWS<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo2"><span style="font-family:Palatino">Therapeutics development for PWS- Genetic therapies; novel pharmaceuticals; drug repurposing for PWS<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">One-year projects; $100,000; 8% IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due March 5, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: February 22.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-009.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hPWrDUiU$">Cellular Senescence Network: Technology Development and Application (UG3 / UH3 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to solicit novel analytics and technologies to identify senescent cells in human tissues This FOA supports the accelerated proof-of-principle
demonstration and validation of promising tools, techniques and methods that can be integrated, scaled and applied to multiple human tissues. The initial two-year UG3 phase will support the development and demonstration of feasibility of these emerging technologies
in the identification and mapping of senescent cells in mammalian tissues. The subsequent UH3 phase is to support initial validation in human tissues, optimization and scale-up, and generation of production level data. Investigators responding to this FOA
must submit both UG3 and UH3 projects as part of a single application. UG3 projects that have met their quantifiable milestones will be administratively considered by NIH staff and prioritized for transition to the UH3 phase, depending on the availability
of funds.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 8, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: February 23.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-033.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hfbaYHeI$" target="_blank">Regulation of Brain Regional and Cell Type Specific Proteome Dynamics in Aging and Alzheimer’s Disease (R01 Clinical
Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the regulation of brain regional and cell-type-specific proteome dynamics in Alzheimer’s disease (AD). Specifically,
this FOA encourages collaborative approaches to design and implement novel, single-cell-based proteomic platforms to comprehensively characterize the dynamics of neuronal proteomes during the course of aging and AD.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 18, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: March 8.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-145.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hQzzGf7A$">HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions,
and/or Suicide Risk (R01 Clinical Trials Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">In April 2018, the National Institutes of Health (NIH) launched the
<a href="https://urldefense.com/v3/__https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hcWsCYmc$" target="_blank">
HEAL (Helping to End Addiction Long-term) Initiative</a>, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. In response to this initiative, the National Institute of Mental Health (NIMH), in partnership
with other NIH Institutes, Centers, and Offices, invites research that will optimize multi-component service delivery interventions for people with opioid use disorder (OUD) and co-occurring conditions, to include mental disorders and/or suicide risk. The
purpose of the initiative is to support studies that will (1) test the overall effectiveness of multi-component interventions for OUD and co-occurring conditions and (2) examine the relative contribution of constituent components to overall effectiveness.
This research will streamline service packages so they only include components that drive clinical improvements for complex conditions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 18, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: March 8.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">HEAL Initiative: HEALthy Brain and Child Development Study (U01 / Collaborative U01 – Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-021.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hNmf1k-8$">U01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-020.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hcsZMG54$">Collaborative U01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of these Funding Opportunity Announcements (FOAs) is to seek applications for unlinked Research Project Sites for the HEALthy Brain and Child Development (HBCD) Study using the cooperative
agreement award mechanism. It is expected that investigators, upon funding, will work jointly with NIH scientific staff to assist, guide, coordinate, or participate in project activities. These FOAs seek applications to create a consortium of research sites
in service of the nationwide, multi-site, multi-modal, longitudinal cohort HBCD Study to prospectively examine brain and behavioral development from birth through childhood, including an emphasis on understanding the impact of in utero substance exposure on
outcomes. Research sites will enroll pregnant women and collect data from them and their children using methodologies that include neuroimaging, neurophysiology, behavioral and cognitive assessments and collection of biospecimens.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 31, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: March 18.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAS-21-031.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hDjJ3R9Q$">Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases that align with the HIV/AIDS research
priorities outlined by the NIH Office of AIDS Research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires January 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for May 5 standard date: April 22.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAS-20-121.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hS9muP_8$">Research Towards Developing a Cure for HBV in HIV/HBV Co-Infection (R21 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative basic, translational, and clinical research to identify and address the challenges to achieving
hepatitis B virus (HBV) cure in the presence of human immunodeficiency virus (HIV).<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires January 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for May 7 standard date: April 26.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-270.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h1ExGtP4$" target="_blank">NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated
clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 12, 2021; September 14, 2021; January 12, 2022; May 13, 2022; September 14, 2022; January 13, 2023; and May 12, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for May 2021 due date: April 29.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-083.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h5Alzsqo$" target="_blank">NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with
high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 14, 2021; September 13, 2021; January 14, 2022; May 13, 2022; September 13, 2022; January 13, 2023; May 13, 2023; September 14, 2023; and January 13, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for May 2021 due date: May 3.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-077.html__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1h68bRp-4$">Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this Funding Opportunity Announcement is to support research to define the mechanisms regulating the establishment, development and maintenance of immunity throughout childhood (from birth
to less than 18 years of age), including the impact of pathogenic or commensal microbes or vaccination against infectious diseases, allergens or environmental pollutants on immune ontogeny and function. This program will establish collaborations among immunologists,
neonatologists, pediatricians, systems biologists, and microbiologists to expand our knowledge of the developing immune system. Knowledge obtained through this program may be applied to the design of improved vaccines and immunotherapies to combat infections
or treat/prevent immune-mediated diseases in this vulnerable population.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due June 4, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: May 24.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://emdrresearchfoundation.org/research-grants/25000-emdr-research-grant-award/__;!!PhOWcWs!iazbU3z_yhmSwFHlpAtz4moPIL37sHbzxgVfdAEqFqvOuGTgU0jP8OoktoOE7ba_K8XX0yQCqh1hLDPxDag$">EMDR Foundation Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Grant awards of up to $25,000 are available for post-doctoral students, university faculty, or clinicians conducting research on Eye Movement Desensitization and Reprocessing (EMDR). Current research priorities
include: <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">1st Priority – Advancing Evidence Based Practice:</span></b><span style="font-family:Palatino"> Increase the availability of quality EMDR research in areas where we already have a foot-hold in the literature
but where more evidence is needed. Specifically, those areas are in the use of EMDR therapy to treat:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Anxiety<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Depression<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Military PTSD<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">Phantom Limb Pain<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo3"><span style="font-family:Palatino">To enhance recovery from the impact of cardiac events and the diagnosis and treatment of cancer<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">2nd Priority – Addressing the Global Burden of Trauma:</span></b><span style="font-family:Palatino"> Investigate the use of EMDR in natural or man-made disaster responses, by determining the effectiveness
of the following protocols: early intervention protocols, the child or adult group protocols, or the use of EMDR standard protocols in disaster response.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">3rd Priority – Building Clinical Evidence:</span></b><span style="font-family:Palatino"> There are a number of areas where EMDR therapy is being used, clinical observations are positive, and there are
some research indicators of success. However, more research is needed to build a body of literature in these populations or diagnostic categories, including but not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo4"><span style="font-family:Palatino">Addictions<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo4"><span style="font-family:Palatino">Eating disorders<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo4"><span style="font-family:Palatino">Dissociative disorders<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo4"><span style="font-family:Palatino">Additional medical/somatic conditions<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo4"><span style="font-family:Palatino">Suicide prevention and/or to address the impact of suicide<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">These priorities apply to research across the lifespan.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due July 1, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: June 21.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69">CoM’s
unofficial funding opportunities blog</a>.</span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>